The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 4
- Kiyoi H, 1999, Blood, 93, 3074
- Valk PJM, 2004, Haematologica, 89, 106
- Touw I, 1991, Leukemia, 5, 687
- Lilly M, 1992, Oncogene, 7, 727
Cited by
Items 601–700 of 1,000
CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia
Korthuis, P. M., Berger, G., Bakker, B., Geugien, M., Jaques, J., de Haan, G., Schuringa, J. J., Vellenga, E., & Schepers, H. (2014) · Leukemia · doi:10.1038/leu.2014.259 · Cited by 29
Chen, P., Chen, Y., Gao, W.-Y., Wu, M., & Yen, J.-H. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b05680 · Cited by 29
Xu, Z., Ma, J., Zhou, J., Wen, X., Yao, D., Zhang, W., Ji, R., Wu, D., Tang, L., Deng, Z., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1851-1 · Cited by 32
Growing Applications and Advancements in Microarray Technology and Analysis Tools
Peeters, J. K., & van der Spek, P. J. (2005) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:43:1:149 · Cited by 29
“(22) with very large 156 Peeters and Van der Spek”
BackgroundMethodChallenges of predicting treatment response in patients with rheumatoid arthritis
Smolen, J. S., & Aletaha, D. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0050 · Cited by 29
“Such an approach not only utilizes the idea of predictive profiles of disease course, treatment response, risk of adverse events or outcome”
MethodEnhanced expression of FHL2 leads to abnormal myelopoiesis in vivo
Qian, Z., Mao, L., Fernald, A. A., Yu, H., Luo, R. T., Jiang, Y. Q., Anastasi, J., Valk, P. J. M., Delwel, R., & Beau, M. M. L. (2009) · Leukemia · doi:10.1038/leu.2009.78 · Cited by 29
Self-citationRokutan, K., Morita, K., Masuda, K., Tominaga, K., Shikishima, M., Teshima-Kondo, S., Omori, T., & Sekiyama, A. (2005) · The Journal of Medical Investigation · doi:10.2152/jmi.52.137 · Cited by 31
RNA Stabilization of Peripheral Blood and Profiling by Bead Chip Analysis
Debey‐Pascher, S., Eggle, D., & Schultze, J. L. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-553-4_13 · Cited by 29
Current therapeutic strategies for acute myeloid leukaemia
Kolitz, J. E. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06219.x · Cited by 29
Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays
Assassi, S., & Tan, F. K. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000179943.27777.b1 · Cited by 29
Kandilci, A., & Grosveld, G. C. (2009) · Blood · doi:10.1182/blood-2009-02-205443 · Cited by 28
Vidovic, K., Svensson, E., Nilsson, B., Thuresson, B., Olofsson, T., Lennartsson, A., & Gullberg, U. (2010) · Leukemia · doi:10.1038/leu.2010.33 · Cited by 28
Moving the needle: Optimizing classification for glioma
Verhaak, R. G. W. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4740 · Cited by 28
Self-citationVoigt, A. P., Brodersen, L. E., Alonzo, T. A., Gerbing, R. B., Menssen, A. J., Wilson, E. R., Kahwash, S. B., Raimondi, S. C., Hirsch, B. A., Gamis, A. S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.169029 · Cited by 28
Numata, A., Kwok, H. S., Kawasaki, A., Li, J., Zhou, Q.-L., Kerry, J., Benoukraf, T., Bararia, D., Li, F., Ballabio, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03854-0 · Cited by 28
Self-citationImpact of Cytogenetics on Clinical Outcome in AML
Grimwade, D. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-322-6_8 · Cited by 28
“In support ofthis notion, microarray analysis has shown that gene expression profiles of cases with cryptic rearrangements cluster with those cases with the overt respective cytogenetic lesion (24, 25 ).”
BackgroundSchemionek, M., Masouleh, B. K., Klaile, Y., Krug, U. O., Hebestreit, K., Schubert, C., Dugas, M., Büchner, T., Wormann, B. J., Hiddemann, W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125783 · Cited by 28
“Gene expression microarray and patient outcome data were obtained from the GEO database accession numbers GSE1159 [16], GSE15646 [17], GSE8023[18] and GSE12417[19].”
MethodAbdul-Nabi, A. M., Yassin, E. R., Varghese, N., Deshmukh, H., & Yaseen, N. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012464 · Cited by 34
“On the other hand, many of the deregulated genes we identified have not been previously identified in molecular signatures from patients with the corresponding oncogene [38,39,40,41,42,43,44].”
BackgroundTang, Z. Q., Han, L., Lin, H., Cui, J., Jia, J., Low, B. C., Li, B. W., & Chen, Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1601 · Cited by 28
“Cancer genes (oncogenes) HMGA1 (1), ETS2 (1) NCOA4 Cancer genes (tumor suppressors) MXI1 (1), TPM1 (2), CDH3 (2) CDX1, PRKACA, CREB5, PPP2R5C, CNNM4 Cancer genes (angiogenesis genes) PECAM1, CCL14 Tumor immune tolerance genes IL1R2 Cancer genes (other types) MYH9 (7), S100P (3), HSP90AB1 (1) IFI6 Tumor markers MUC2 (1…”
Current status of gene expression profiling in the diagnosis and management of acute leukaemia
Bacher, U., Kohlmann, A., & Haferlach, T. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07656.x · Cited by 28
“The majority of leukaemia subtypes, as defined by their phenotypes and genotypes, can be predicted based on specific gene expression patterns (‘class prediction’) (Golub et al, 1999; Valk et al, 2004; Yeoh et al, 2002; Haferlach et al, 2005a).”
BackgroundConstruction and validation of a bone marrow tissue microarray
Zimpfer, A., Schönberg, S., Lugli, A., Agostinelli, C., Pileri, S. A., Went, P., & Dirnhofer, S. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.035758 · Cited by 28
Gene expression profiling and multiple myeloma
Shaughnessy, J. D., Zhan, F., Barlogie, B., & Stewart, A. K. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.02.003 · Cited by 29
Liu, Y., Ma, J., Ma, Y., Wang, B.-C., Wang, Y., Yuan, J., Zhang, F., Zhao, X., Chen, K., Zhang, X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010813 · Cited by 28
The transcriptional regulation of normal and malignant blood cell development
Edginton‐White, B., & Bonifer, C. (2021) · FEBS Journal · doi:10.1111/febs.15735 · Cited by 28
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
Lopes, B. A., Poubel, C. P., Teixeira, C. E., Caye‐Eude, A., Cavé, H., Meyer, C., Marschalek, R., Boroni, M., & Emerenciano, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.749472 · Cited by 28
“As a consequence, several studies identified LAMP5 overexpression in KMT2A-r leukemia (Ross et al., 2004; Valk et al., 2004; Zangrando et al., 2009; Stam et al., 2010; Wang et al., 2019).”
BackgroundShao, Y.-L., Li, Y.-Q., Li, M., Wang, L., Zhou, H.-S., Liu, D., Yu, L., Lin, J., & Gao, X. (2023) · Leukemia · doi:10.1038/s41375-023-01904-1 · Cited by 28
“KDM4B is upregulated and strongly predicts inferior prognosis in t(8;21) AML To explore the relationship between HIF1α-WTAP axis and KDM4B expression and investigate the biological roles of KDM4B in the malignant features of t(8;21) AML cells, we firstly analyzed the Leukemia (2023) 37:1254 – 1267 expression data of K…”
BackgroundMethodInfluentialConstitutive IRF8 expression inhibits AML by activation of repressed immune response signaling
Sharma, A. K., Yun, H., Jyotsana, N., Chaturvedi, A., Schwarzer, A., Yung, E., Lai, C. K., Kuchenbauer, F. C., Argiropoulos, B., Görlich, K., et al. (2014) · Leukemia · doi:10.1038/leu.2014.162 · Cited by 28
Retinal pigment epithelial cells display specific transcriptional responses upon TNF-α stimulation
Korthagen, N. M., van Bilsen, K., Swagemakers, S. M. A., van de Peppel, J., Bastiaans, J., van der Spek, P. J., van Hagen, P. M., & Dik, W. A. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306309 · Cited by 27
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
Ragaini, S., Wagner, S., Marconi, G., Parisi, S., Sartor, C., Nanni, J., Cristiano, G., Talami, A., Olivi, M., Očadlíková, D., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004878 · Cited by 33
Beekman, R., Valkhof, M. G., Erkeland, S. J., Taskesen, E., Ročková, V., Peeters, J. K., Valk, P. J. M., Löwenberg, B., & Touw, I. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026537 · Cited by 27
“Purified AML blasts were obtained following informed consent as described [31].”
MethodSelf-citationErkeland, S. J., Verhaak, R. G. W., Valk, P. J. M., Delwel, R., Löwenberg, B., & Touw, I. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2908 · Cited by 27
Self-citationGladkevich, A. V., Nelemans, S. A., Kauffman, H. F., & Korf, J. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.317 · Cited by 31
“gene expression profiles have been derived from cancer research [1, 2, 3, 4] using tumor tissue and peripheral blood mononuclear cells (PBMCs).”
BackgroundMethodImpact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
Yun, H., Damm, F., Yap, D., Schwarzer, A., Chaturvedi, A., Jyotsana, N., Lübbert, M., Bullinger, L., Döhner, K., Geffers, R., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.101386 · Cited by 26
Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients
Langemeijer, S. M. C., Mariani, N., Knops, R., Gilissen, C., Woestenenk, R., de Witte, T., Huls, G. A., van der Reijden, B. A., & Jansen, J. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165582 · Cited by 29
Singh, A. A., Mandoli, A., Prange, K. H. M., Laakso, M., & Martens, J. H. A. (2016) · Oncotarget · doi:10.18632/oncotarget.14150 · Cited by 26
“Together with large cohorts of gene expression data from AML patients that have become available [20, 21, 22], it now provides an opportunity to perform comparative-integrative analysis of these oncofusion proteins to identify exclusive and mutually shared structural and functional features.”
InfluentialReikvam, H., Aasebø, E., Brenner, A. K., Bartaula-Brevik, S., Grønningsæter, I. S., Forthun, R. B., Hovland, R., & Bruserud, Ø. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070970 · Cited by 26
Taskesen, E., Staal, F. J. T., & Reinders, M. J. T. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s4-s4 · Cited by 26
“Over the past years, genetic and epigenetic studies have, independently from each other, provided important new insights in the underlying pathology of Acute Myeloid Leukemia (AML) [9-11].”
BackgroundNowek, K., Sun, S. M., Bullinger, L., Bindels, E. M., Exalto, C., Dijkstra, M. K., van Lom, K., Döhner, H., Erkeland, S. J., Löwenberg, B., et al. (2015) · Leukemia · doi:10.1038/leu.2015.183 · Cited by 26
Self-citationAlachkar, H., Mutonga, M., Malnassy, G., Park, J.-H., Fulton, N. C., Woods, A., Meng, L., Kline, J. P., Raca, G., Odenike, O. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5418 · Cited by 27
Negative effects of GM-CSF signaling in a murine model of t(8;21)–induced leukemia
Matsuura, S., Yan, M., Lo, M., Ahn, E.-Y., Weng, S., Dangoor, D., Matin, M., Higashi, T., Feng, G., & Zhang, D. (2012) · Blood · doi:10.1182/blood-2011-04-350694 · Cited by 29
The role of gene expression profiling in drug discovery
Bates, S. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.06.009 · Cited by 26
Andersson, A., Paulsson, K. M., Lilljebjörn, H., Lassen, C., Strömbeck, B., Heldrup, J., Behrendtz, M., Johansson, B., & Fioretos, T. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20508 · Cited by 26
“To investigate further the expression pattern associated with FLT3, the genes identified with prediction analysis of microarrays (PAM) correlating with FLT3 mutational status in two previous AML studies (Lacayo et al., 2004; Valk et al., 2004) were used.”
BackgroundMethodInfluentialMarstrand, T. T., Borup, R., Willer, A., Borregaard, N., Sandelin, A., Porse, B. T., & Theilgaard‐Mönch, K. (2010) · Leukemia · doi:10.1038/leu.2010.95 · Cited by 26
Xiang, L., Li, M., Liu, Y., Cen, J.-N., Chen, Z., Xiao, Z., Xie, X., Cao, X.-S., & Gu, W. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1729-x · Cited by 26
“Previous studies reported MN1 overexpression in subtypes of AML [24, 25].”
BackgroundDiakiw, S. M., Kok, C. H., To, L. B., Lewis, I. D., Brown, A. L., & D’Andrea, R. J. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.09.013 · Cited by 26
Visual Analytics in the Pharmaceutical Industry
Saffer, J. D., Burnett, V. L., Chen, G., & van der Spek, P. J. (2004) · IEEE Computer Graphics and Applications · doi:10.1109/mcg.2004.40 · Cited by 26
Wu, Z., Zhuang, H., Yu, Q., Zhang, X., Jiang, X., Lu, X., Xu, Y., Yang, L., Wu, B., Ma, A., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.016 · Cited by 26
“016 Background As a genetically heterogeneous group of diseases, acute myeloid leukemia (AML) shows distinct features in the fields of clinicopathology, cytogenetics and genetics [1,2].”
BackgroundZamir, E., Geiger, B., Cohen, N., Kam, Z., & Katz, B. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05471.x · Cited by 26
“…research, for example, the huge volume of available genomic or proteomic data synergized with the development of powerful algorithms for the search of gene sequence homologies, including in prognostic evaluation of leukaemias (Alon et al, 1999; Bullinger et al, 2004; Valk et al, 2004).”
BackgroundVerhaak, R. G. W., Staal, F. J. T., Valk, P. J. M., Löwenberg, B., Reinders, M. J. T., & de Ridder, D. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-105 · Cited by 26
“Samples in all datasets (4 pre-processing methods) were clustered using k -means clustering and hierarchical clustering on both correlation distance matrices, in which the distance between two samples x and y is defined as 1-ρ xy ; and Euclidean distance matrices, as used in [19].”
MethodSelf-citationInsight into the molecular pathogenesis of myeloid malignancies
Haferlach, T., Bacher, U., Haferlach, C., Kern, W., & Schnittger, S. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3280168490 · Cited by 26
Deep profiling of gene expression across 18 human cancers
Qiu, W., Dincer, A. B., Janizek, J. D., Çelik, S., Pittet, M. J., Naxerova, K., & Lee, S. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01290-8 · Cited by 27
“Similarly, AML-specific genes comprised transcripts that had previously been associated with AML subtypes (such as HOXA7 , TRH , MYL4 , ANK1 ) 55,56 (Fig.”
Saito, Y., Sawa, D., Kinoshita, M., Yamada, A. Y., Kamimura, S., Suekane, A., Ogoh, H., Matsuo, H., Adachi, S., Taga, T., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.225953 · Cited by 26
Onish, C., Mori, S., Hirade, T., Abe, M., Taketani, T., Suzumiya, J., Sugimoto, T., Yamaguchi, S., Kapur, R., & Fukuda, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568287 · Cited by 25
“Comparison of the Cxcr4 expression levels in different human AML cell lines using gene expression data from the public gene expression profile database (26) demonstrated that Cxcr4 mRNA expression was significantly lower in ITD-FLT3 AML cells (n 78) than in ITD-FLT3 AML cells (n 190, p 0.”
BackgroundKumar, A., Sen, A., & Das, P. K. (2010) · International Journal of Advances in Pharmaceutical Sciences · doi:10.5138/ijaps.2010.0976.1055.01001 · Cited by 25
van Helden, Y. G. J., Godschalk, R., Lintig, J. V., Lietz, G., Landrier, J., Bonet, M. L., van Schooten, F., & Keijer, J. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100194 · Cited by 25
Transcriptional memory of cells of origin overrides β‐catenin requirement of MLL cancer stem cells
Siriboonpiputtana, T., Zeisig, B. B., Zarowiecki, M., Fung, T. K., Mallardo, M., Tsai, C., Lau, P. N. I., Hoang, Q. C., Veiga, P., Barnes, J. L., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201797994 · Cited by 26
“…cells of origin transcriptional memory gene signature in human leukemia, we employed it to stratify 1,290 human AML patients from multiple independent centers (Valk et al, 2004, Raponi et al, 2007, 2008; Metzeler et al, 2008; Wouters et al, 2009; Cancer Genome Atlas Research N, 2013; Dataset EV2E).”
Liu, S., Xing, Y., Lu, W., Li, S., Tian, Z., Xing, H., Tang, K., Xu, Y., Rao, Q., Wang, M., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.192773 · Cited by 27
Walker, C. J., Kohlschmidt, J., Eisfeld, A., Mrózek, K., Liyanarachchi, S., Song, C. W., Nicolet, D., Blachly, J. S., Bill, M., Papaioannou, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0725 · Cited by 25
Montefiori, L. E., & Mullighan, C. G. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101329 · Cited by 31
Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1high leukemia cells
Ichihara, E., Kaneda‐Nakashima, K., Saito, Y., Yamakawa, N., & Morishita, K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.10.061 · Cited by 25
“The gene expression profiles of EVI1 AML patients are quite similar to those of control CD34 cells [6], and furthermore, analysis of EVI1-deficient mice has shown that EVI1 is required for the maintenance of hematopoietic stem cells (HSCs), suggesting that EVI1 leukemia cells may have stem cell-like phenotypes.”
FDR control with adaptive procedures and FDR monotonicity
Zeisel, A., Zuk, O., & Domany, E. (2011) · The Annals of Applied Statistics · doi:10.1214/10-aoas399 · Cited by 27
“…et al. (2006); Graudens et al. (2006); Koinuma et al. (2006); Laiho et al. (2007); Miller et al. (2005); Pawitan et al. (2005); Ross et al. (2003); Valk et al. (2004); van de Vijver et al. (2002); Wang et al. (2005); Watanabe et al. (2006); Yeoh et al. (2002); Zhao et al. (2004); Zou et al.…”
MethodThach, D., Agan, B. K., Olsen, C., Diao, J., Lin, B., Gómez, J. L., Jesse, M., Jenkins, M., Rowley, R. K., Hanson, E., et al. (2005) · Genes and Immunity · doi:10.1038/sj.gene.6364244 · Cited by 25
Microarrays: a monitoring tool for transplant patients?
Weintraub, L. A., & Sarwal, M. (2006) · Transplant International · doi:10.1111/j.1432-2277.2006.00349.x · Cited by 25
Bench, A. J., Erber, W. N., & Scott, M. A. (2005) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.2005.00701.x · Cited by 28
Erkeland, S. J., Palande, K. K., Valkhof, M. G., Gits, J., Oorschot, A. A. D.-V., & Touw, I. P. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.02.027 · Cited by 25
“We determined XNIP transcript levels in different classes of adult and peditric AML patients [7,10].”
BackgroundMethodInfluentialFan, H., Wang, F., Zeng, A. G. X., Murison, A., Tomczak, K. J., Hao, D., Jelloul, F. Z., Wang, B., Barrodia, P., Liang, S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05120-6 · Cited by 25
Caudell, D. L., Harper, D. P., Novak, R. L., Pierce, R. M., Slape, C. I., Wolff, L., & Aplan, P. D. (2009) · Blood · doi:10.1182/blood-2009-04-216184 · Cited by 29
Rommer, A., Steinmetz, B., Herbst, F., Hackl, H., Heffeter, P., Heilos, D., Filipits, M., Steinleitner, K., Hemmati, S., Herbacek, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056308 · Cited by 26
“stem and progenitor cells but not in mature blood cells [1,2,3,4], is associated with a poor prognosis in myeloid leukemias [2,5,6,7,8,9,10,11,12,13].”
BackgroundAberrant DNA methylation of the transcription factor C/EBPα in acute myelogenous leukemia
Jost, E., do Ó, N., Wilop, S., Herman, J. G., Osieka, R., & Galm, O. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.07.027 · Cited by 24
Bergerson, R. J., Collier, L. S., Sarver, A. L., Been, R. A., Lugthart, S., Diers, M. D., Zuber, J. A., Rappaport, A., Nixon, M. J., Silverstein, K. A. T., et al. (2012) · Blood · doi:10.1182/blood-2010-04-281428 · Cited by 26
Self-citationAnguita, E., Gupta, R., Olariu, V., Valk, P. J. M., Peterson, C., Delwel, R., & Enver, T. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.02.002 · Cited by 26
“gene expression profiles were uncovered (Valk et al., 2004).”
MethodResultInfluentialSelf-citationFloeth, M., Elges, S., Gerß, J., Schwöppe, C., Keßler, T., Herold, T., Wardelmann, E., Berdel, W. E., Lenz, G., Mikesch, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16853 · Cited by 24
“0 chips and has been published previously.(12,13) Gene expression data and clinical information are publicly available (GSE6891).”
BackgroundLee, D.-H., Kang, S.-H., Choi, D., Ko, M., Choi, E., Ahn, H., Min, H., Oh, S. J., Lee, M. S., Park, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.006 · Cited by 25
Erkeland, S. J., Aarts, L. H. J., Irandoust, M. I., Roovers, O., KLOMP, A. E. M., Valkhof, M. G., Gits, J., Eyckerman, S., Tavernier, J. H., & Touw, I. P. (2006) · Oncogene · doi:10.1038/sj.onc.1210004 · Cited by 24
“WSB-2 expression in human AML Real-time PCR was performed on complementary DNA from 260 AML patients using an Applied Biosystems 7900 instrument (Applied Biosystems, Weiterstadt, Germany) and SYBR Green PCR Master Mix (Applied Biosystems) (Erkeland et al., 2003; Valk et al., 2004).”
BackgroundMethodInfluentialDifferential involvement of E2A-corepressor interactions in distinct leukemogenic pathways
Gow, C., Guo, C. H., Wang, D., Hu, Q., & Zhang, J. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt855 · Cited by 24
“Its expression, however, is silenced by AML1-ETO in Kasumi-1 cells (Figure 6C) and in patients with t(8;21) AML (64).”
BackgroundThe challenge of risk stratification in acute myeloid leukemia with normal karyotype
Zaidi, S. Z. A., Owaidah, T. M., Sharif, F. A., Ahmed, S. Y., Chaudhri, N. A., & Aljurf, M. D. (2008) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(08)50023-9 · Cited by 24
MicroRNAs: new players in acute myeloid leukaemia
Havelange, V., Garzon, R., & Croce, C. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605232 · Cited by 24
“In some cases, the GEP signatures were able to predict outcome (Bullinger et al, 2004; Ross et al, 2004; Valk et al, 2004).”
BackgroundBlood-based transcriptomics: leukemias and beyond
Staratschek‐Jox, A., Claßen, S., Gaarz, A., Debey‐Pascher, S., & Schultze, J. L. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.9 · Cited by 24
Thivakaran, A., Botezatu, L., Hönes, J. M., Schütte, J., Vaßen, L., Al-Matary, Y. S., Patnana, P. K., Zeller, A. C., Heuser, M., Thol, F. R., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.167288 · Cited by 24
“CD34 leukemic cells represent a fraction in which LSCs are enriched, whereas CD34 cells from healthy donors represent a fraction of cells in which HSCs are enriched.(21,30)GFI1B showed lower expression in CD34 AML blasts compared to CD34 control HSCs (Figure 1A).”
BackgroundResultInfluentialKohlmann, A., Haschke‐Becher, E., Wimmer, B., Huber-Wechselberger, A., Meyer‐Monard, S., Huxol, H., Siegler, U., Rossier, M. F., Matthes, T., Rebsamen, M. C., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.108506 · Cited by 24
Nilsson, B., Håkansson, P., Johansson, M., Nelander, S., & Fioretos, T. (2007) · Genome biology · doi:10.1186/gb-2007-8-5-r74 · Cited by 24
“The Valk dataset [18] and the Radich dataset [19] were obtained from the NCBI Gene Expression Omnibus repository [20], accessions GSE1159 and GSE4170, respectively.”
MethodAssessment of human stress and depression by DNA microarray analysis
Ohmori, T., Morita, K., Saito, T., Ohta, M., Ueno, S., & Rokutan, K. (2005) · The Journal of Medical Investigation · doi:10.2152/jmi.52.266 · Cited by 26
“predictors in adult acute myeloid leukemia (5) and breast cancer (6, 7).”
BackgroundNowek, K., Sun, S. M., Dijkstra, M. K., Bullinger, L., Döhner, H., Erkeland, S. J., Löwenberg, B., & Jongen‐Lavrencic, M. (2015) · Leukemia · doi:10.1038/leu.2015.282 · Cited by 24
Self-citationTaskesen, E., Huisman, S. M. H., Mahfouz, A. E., Krijthe, J. H., de Ridder, J., van de Stolpe, A., van den Akker, E. B., Verheagh, W., & Reinders, M. J. T. (2016) · Scientific Reports · doi:10.1038/srep24949 · Cited by 23
“Overall, the grouping of samples is in line with previous results 6,9,35 , e.g., clustering of samples with: i ) t(8;21), Cluster 4; ii ) t(15;17), Cluster 11; iii ) inv(16), Cluster 13; and iv ) complex karyotype in Cluster 7.”
BackgroundResultShen, T., Mei, L., Qiu, Y., & Shi, Z. (2016) · Oncology Letters · doi:10.3892/ol.2016.4947 · Cited by 24
“HOMER3 is overex6pressed in acute myeloid leukemia (AML), and decreased expression of HOMER3 is associated with poor prognosis in AML (27,28).”
Nutrigenomics: An Interface of Gene-Diet-Disease Interaction
Mondal, S., & Panda, D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94602 · Cited by 28
“[23] Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R.”
BackgroundShi, J., Fu, L. N., Ang, Q., Wang, G., Zhu, J., & Wang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6226 · Cited by 23
“The samples all contained 80%‐100% blast cells after thawing [46].”
BackgroundPerugini, M., Kok, C. H., Brown, A. L., Wilkinson, C. R., Salerno, D. G., Young, S. M., Diakiw, S. M., Lewis, I., Gonda, T. J., & D’Andrea, R. J. (2009) · Leukemia · doi:10.1038/leu.2008.349 · Cited by 26
Etiology of Acute Myeloid Leukemia in the Elderly
Bowen, D. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.01.005 · Cited by 23
Percio, S., Coltella, N., Grisanti, S., Bernardi, R., & Pattini, L. (2014) · Genome Medicine · doi:10.1186/s13073-014-0084-4 · Cited by 23
“Using these 119 genes as a seed (Additional file 1), we reconstructed two distinct transcriptional networks based on two data sets of gene expression profiles in AML: the first data set includes 293 AML samples, out of which 19 are classified as M3, analyzed by Affymetrix HG-U133A Array [17]; the second data set conta…”
MethodInfluentialBarabé, F., Gil, L., Celton, M., Bergeron, A., Lamontagne, V., Roques, É., Lagacé, K., Forest, A., Johnson, R. M., Pécheux, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.302 · Cited by 23
Data mining for mutation-specific targets in acute myeloid leukemia
Benard, B. A., Gentles, A. J., Köhnke, T., Majeti, R., & Thomas, D. (2019) · Leukemia · doi:10.1038/s41375-019-0387-y · Cited by 26
Wang, F., Huang, J., Guo, T., Zheng, Y., Zhang, L., Zhang, D., Wang, F., Naren, D., Cui, Y., Liu, X., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114538 · Cited by 23
Acute Myeloid Leukemia Subgroups Identified by Pathway-Restricted Gene Expression Signatures
Serrano, E., Lasa, A., Perea, G., Carnicer, M. J., Brunet, S., Aventin, A. M., Sierra, J., & Nomdedeu, J. F. (2006) · Acta Haematologica · doi:10.1159/000093636 · Cited by 26
“Integrated data obtained from massive new technologies are currently employed to determine the biology of neoplasia in humans. Profiling strategies have improved our knowledge on the genetic mechanisms underlying cancer [ , ,”
MethodShang, L., Chen, X., Liu, Y., Cai, X., Shi, Y., Shi, L., Li, Y., Song, Z., Zheng, B., Sun, W., et al. (2018) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12916 · Cited by 22
Jin, P., Jin, Q., Wang, X., Zhao, M., Dong, F., Jiang, G., Li, Z., Shen, J., Zhang, W., Wu, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1618 · Cited by 24
“Toextractthecoremoleculareffectorsof fi tnessthatrelatetopatient outcomes across a wide spectrum of AML cytogenetic subtypes, we interrogated the HOVON dataset (25), in which 230 of the 280 AFGs were captured.”
Identification of new markers discriminating between myeloid and lymphoid acute leukemia
Haouas, H., Haouas, S., Uzan, G., & Hafsia, A. (2010) · Hematology · doi:10.1179/102453310x12647083620769 · Cited by 22
The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies
Heuston, E. F., Lemon, K. T., & Arceci, R. J. (2011) · Frontiers in Genetics · doi:10.3389/fgene.2011.00094 · Cited by 22
“…numerous groups have identified mRNA signatures distinguishing AML subclasses, several groups have associated miRNA signatures with cytogenetic abnormalities and predictors www.frontiersin.org December 2011 | Volume 2 | Article 94 | 3 of outcome in AML (Bullinger et al., 2004; Valk et al., 2004).”
BackgroundA novel ensemble of classifiers that use biological relevant gene sets for microarray classification
Reboiro‐Jato, M., Díaz, F., Glez‐Peña, D., & Fdez‐Riverola, F. (2014) · Applied Soft Computing · doi:10.1016/j.asoc.2014.01.002 · Cited by 27
Cross-validation under separate sampling: strong bias and how to correct it
Braga-Neto, U., Zollanvari, A., & Dougherty, E. R. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu527 · Cited by 22
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.